LRMR
Larimar Therapeutics, Inc.
Next earnings Aug 12, 2026 (after close) · consensus $-0.39 EPS
Last earnings -5.1% on 2026-05-14
$3.68
▲ +0.55%$3.68▲ +36.80%
over 1Y
L $2.42EODHDH $5.95
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+0.5%
1W+8.2%
1M+6.1%
3M-19.5%
YTD+6.1%
1Y+36.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.87x).
Larimar Therapeutics, Inc. shows $0.00 in FY2019 revenue, and -212.2% ROE.
Sources: SEC EDGAR (CIK 0001374690, latest 10-Q filed 2026-05-14) · EODHD · as of 6/22/2026, 9:52:08 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.